1
|
Cremers S, Tucker GT, Aronson JK, Ritter JM, Cohen AF. The British Journal of Clinical Pharmacology: The first 50 years. Br J Clin Pharmacol 2024; 90:4-11. [PMID: 38153173 DOI: 10.1111/bcp.15952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 10/29/2023] [Accepted: 10/30/2023] [Indexed: 12/29/2023] Open
Abstract
The British Journal of Clinical Pharmacology celebrates its 50th anniversary of publication in 2023. Here four previous Editors-in-Chief and the current Editor reflect on the Journal's history and the changes that have occurred during that time.
Collapse
Affiliation(s)
- Serge Cremers
- Departments of Pathology & Cell Biology and Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA
| | - Geoffrey T Tucker
- School of Medicine and Population Health, University of Sheffield, Sheffield, UK
| | - Jeffrey K Aronson
- Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Oxford, UK
| | - James M Ritter
- Department of Clinical Pharmacology, Clinical Research Facility, St Thomas' Hospital, London, UK
| | - Adam F Cohen
- Leiden University Medical Centre and Centre for Human Drug Research, Leiden, The Netherlands
| |
Collapse
|
2
|
Fang J, Zeng W. A meta-analysis of the clinical efficacy of rhBNP in treating patients with acute myocardial infarction and heart failure. Am J Transl Res 2021; 13:2410-2421. [PMID: 34017399 PMCID: PMC8129417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Accepted: 01/11/2021] [Indexed: 06/12/2023]
Abstract
OBJECTIVE To explore the clinical efficacy of rhBNP in patients with acute myocardial infarction (AMI) and heart failure (HF). METHODS A systematic review and a meta-analysis were performed using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. On May 30, 2020, we consulted the electronic databases PubMed, EBSCO, Elsevier, Springer, Wiley, and Cochrane using the keywords "acute coronary syndrome (ACS)", "brain natriuretic peptide (BNP)", and "acute myocardial infarction (AMI)". The quality of the data included in the study was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions. The results of the clinical randomized controlled study reports were analyzed using Review Manager 5.1.0. RESULTS A total of nine, clinical, randomized, controlled studies were included. The effective rate in the rhBNP group was significantly higher than it was in the control group (Z = 9.50, P < 0.00001). The patients in the rhBNP group showed remarkably shorter hospital stays (Z = 24.43, P < 0.00001) and markedly increased left ventricular ejection fractions (LVEF) (Z = 245.53, P < 0.00001). Compared with the LVEF in the control group, the LVEF in the rhBNP group was significantly increased (Z = 3.55, P = 0.0004), but the rate of cardiac hypotension (Z = 3.55, P = 0.0004) and the headache incidence rate in the rhBNP group (Z = 2.3, P = 0.04) were not elevated. The rhBNP group showed no increase in either the low heart rate (Z = 1.22, P = 0.22) or the rate of renal insufficiency (Z = 0.35, P = 0.73). CONCLUSION The meta-analysis suggests that, compared with the conventional treatment of patients with AMI and HF, rhBNP can markedly improve the clinical efficacy and myocardial functions and shorten the hospital stays, without elevating the rate of adverse reactions, such as hypotension, headaches, low heart rate, and renal insufficiency.
Collapse
Affiliation(s)
- Jingyun Fang
- Emergency Department, Ganzhou People's Hospital Ganzhou 341000, Jiangxi Province, China
| | - Weilan Zeng
- Emergency Department, Ganzhou People's Hospital Ganzhou 341000, Jiangxi Province, China
| |
Collapse
|
3
|
Zhao X, Zhang DQ, Song R, Zhang G. Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis. J Int Med Res 2020; 48:300060519897194. [PMID: 31948318 PMCID: PMC7113720 DOI: 10.1177/0300060519897194] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Objective This meta-analysis evaluated the efficacy and safety of nesiritide in patients with acute myocardial infarction (AMI) and heart failure. Methods PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception through December 2018. Studies including patients with AMI and heart failure who received nesiritide were identified. Results Ten trials involving 870 participants were included in this meta-analysis. Nesiritide treatment significantly increased left ventricular ejection fraction, cardiac index, and 24- and 72-hour urine volumes. Additionally, pulmonary capillary wedge pressure, right atrial pressure, and brain natriuretic peptide and N-terminal brain natriuretic peptide levels were significantly decreased in patients treated with nesiritide compared with those treated with control drugs. However, patients treated with nesiritide did not have an increased risk of mortality compared with those treated with control drugs. There were no differences between the two groups with respect to heart rate or the risk of readmission, hypotension, or renal dysfunction. Conclusions Nesiritide appears to be safe for patients with AMI and heart failure, and it improves global cardiac and systemic function.
Collapse
Affiliation(s)
- Xuecheng Zhao
- Department of Emergency Medicine, China-Japan Friendship Hospital, Beijing, China
| | - Da-Qi Zhang
- Department of Neurology, First Affiliated Hospital of Hainan Medical University, Haikou, China
| | - Rongjing Song
- Department of Pharmacy, Peking University People's Hospital, Beijing, China
| | - Guoqiang Zhang
- Department of Emergency Medicine, China-Japan Friendship Hospital, Beijing, China
| |
Collapse
|
4
|
Cohen A, Pattanaik S, Kumar P, Bies RR, de Boer A, Ferro A, Gilchrist A, Isbister GK, Ross S, Webb AJ. Organised crime against the academic peer review system. Br J Clin Pharmacol 2018; 81:1012-7. [PMID: 27211251 DOI: 10.1111/bcp.12992] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Accepted: 04/27/2016] [Indexed: 11/30/2022] Open
Affiliation(s)
- Adam Cohen
- Centre for Human Drug Research, Leiden, 2333 CL, The Netherlands
| | - Smita Pattanaik
- PGIMER Pharmacology 4015, Research block B, PGIMER, Chandigarh, 160012, India
| | - Praveen Kumar
- Chandigarh Room number 4019, Research block B, Department of Pharmacology, PGIMER, Chandigarh, 160012, India
| | - Robert R Bies
- Department of Pharmaceutical sciences, State University of New York Buffalo, Buffalo, New York, 14214-8033, USA
| | - Anthonius de Boer
- Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands
| | - Albert Ferro
- Department of Clinical Pharmacology, King's College London, London, SE1 9NH, UK
| | - Annette Gilchrist
- Pharmaceutical Sciences, Midwestern University, Downers Grove, Illinois, 60515, USA
| | - Geoffrey K Isbister
- Clinical Toxicology Research Group, University of Newcastle, Newcastle, New South Wales, 2298, Australia
| | - Sarah Ross
- Perth Royal Infirmary, Perth, PH1 1NX, UK
| | - Andrew J Webb
- Cardiovascular Division, Department of Clinical Pharmacology, King's College London British Heart Foundation Centre, London, SE1 7EH, UK
| |
Collapse
|
5
|
The 10-D assessment and evidence-based medicine tool for authors and peer reviewers in clinical pharmacology
. Int J Clin Pharmacol Ther 2017; 55:639-642. [PMID: 28671061 PMCID: PMC5514613 DOI: 10.5414/cp203073] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/19/2017] [Indexed: 11/18/2022] Open
Abstract
Background: Peer reviewers and authors of clinical pharmacology manuscripts need to meet the standards for Evidence-Based Medicine (EBM) and Good Publication Practices (GPP), and editors of clinical pharmacology journals have to maintain an overview of the peer review process. Methods and results: The peer review process can be monitored and facilitated using the 10-D assessment, which comprises peer review criteria to determine if: 1. design of the study, 2. diagnoses employed, 3. drug molecules involved, 4. dosages applied, 5. data collected, 6. discussion of the findings, 7. deductions made, 8. documentation, 9. declarations, and 10. dHS (drug hypersensitivity syndrome) risk assessment is in accord with the objectives of the study and meet the requirements of EBM and GPP. Conclusions: The 10-D assessment tool, although easy to apply, requires a high level of clinical pharmacology expertise, especially in the fields of drug disposition, pharmacokinetics, and drug action. Its application will facilitate the peer review of clinical research and clinical trial reports and thus promote safety in drug development and pharmacotherapy and meet the needs of Good Publication Practices.
Collapse
|
6
|
Woodcock BG. Peer review in Clinical Pharmacology using the 8-D Assessment. Int J Clin Pharmacol Ther 2017; 55:201-200. [PMID: 28218890 PMCID: PMC5352955 DOI: 10.5414/cp202971] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Accepted: 01/19/2017] [Indexed: 11/18/2022] Open
Abstract
The requirement for editors of clinical pharmacology journals to maintain an overview of the peer review process for manuscripts submitted can be facilitated by use of the 8-D Assessment. The 8-D Assessment comprises peer review criteria to determine if the:1. Design of the study, 2. Diagnoses employed, 3. Drug molecules involved, 4. Dosages applied, 5. Data collected, 6. Discussion of the findings, 7. Deductions made, and 8. Documentation are in accord with the objectives of the study and meet the requirements of evidence-based medicine. This tool, although easy to apply, requires a high level of clinical pharmacology expertise, especially in the fields of drug disposition, pharmacokinetics, and drug action.
Collapse
Affiliation(s)
- Barry G Woodcock
- Dustri Medical Science Publications, Munich-Oberhaching, Germany
| |
Collapse
|
7
|
Retraction: 'rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients: a meta-analysis' by Ming-Yi Lv, Shu-Ling Deng and Xiao-Feng Long. Br J Clin Pharmacol 2016; 81:1005. [PMID: 27086732 DOI: 10.1111/bcp.12933] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
The above article, published online on 28(th) November 2015 in Wiley Online Library (http://onlinelibrary.wiley.com/doi/10.1111/bcp.12788/full), and in volume 81, pp. 174-185, has been retracted by agreement between the authors, the journal Editor in Chief, Professor A Cohen, and John Wiley & Sons Limited. The retraction has been agreed owing to evidence indicating that the peer review of this paper was compromised. The authors were unaware of the actions of the third party responsible for compromising the peer review. Reference Lv M-Y, Deng S-L, Long X-F. rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients: a meta-analysis. Br J Clin Pharmacol 2016; 81: 174-85. doi:10.1111/bcp.12788.
Collapse
|
8
|
Lv MY, Deng SL, Long XF. Retraction. rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients: a meta-analysis. Br J Clin Pharmacol 2015; 81:174-85. [PMID: 26382927 DOI: 10.1111/bcp.12788] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Revised: 09/11/2015] [Accepted: 09/15/2015] [Indexed: 12/27/2022] Open
Abstract
AIMS A meta-analysis was performed to compare the therapeutic outcomes in patients treated for heart failure (HF) with recombinant human brain natriuretic peptide (rhBNP) and dobutamine. METHODS PubMed, Embase and the Chinese Biomedical Database were exhaustively searched to identify studies relevant to this meta-analysis. Eight cohort studies were found suitable for inclusion. Data regarding trial validity, methodological processes and clinical outcomes were extracted. RESULTS Patients treated with rhBNP showed statistically significant reduction of in-hospital mortality and re-admission rates compared with the dobutamine treated patient group (both P < 0.05). Further, the rhBNP treated patient group showed higher survival outcomes, compared with dobutamine treated patients, when the post-treatment follow-up period was longer than 6 months (P < 0.05). Stratified analysis based on ethnicity showed a dramatic decrease of in-hospital mortality among mixed race HF patients receiving rhBNP treatment (P < 0.05), but such decreases were not statistically significant in Asian and Caucasian populations (both P > 0.05). On the other hand, re-admission rates were significantly lower in rhBNP treated Caucasian and mixed race populations (both P < 0.05). Notably, in rhBNP treated group, dose levels of 0.015 and 0.03 incrementally lowered the re-admission rates, displaying dose effect, and the re-admission rates at both rhBNP doses were significantly lower than the dobutamine treated group (both P < 0.05). CONCLUSIONS Our meta-analysis results suggested that rhBNP therapy is associated with lower in-hospital mortality and re-admission rates in HF patients compared to the dobutamine regimen. Nevertheless, large scale prospective, randomized trials are necessary to confirm these findings.
Collapse
Affiliation(s)
- Ming-Yi Lv
- Department of Internal Medicine, ICU, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116000, Liaoning Province, P.R. China
| | - Shu-Ling Deng
- Department of Internal Medicine, ICU, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116000, Liaoning Province, P.R. China
| | - Xiao-Feng Long
- Department of Internal Medicine, ICU, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116000, Liaoning Province, P.R. China
| |
Collapse
|